Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.85)
# 681
Out of 5,090 analysts
215
Total ratings
56.69%
Success rate
7.09%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $305 → $315 | $329.89 | -4.51% | 18 | Nov 6, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $109.60 | +2.19% | 2 | Oct 31, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $925 → $985 | $1,010.31 | -2.51% | 14 | Oct 31, 2025 | |
| GILD Gilead Sciences | Reiterates: Overweight | $135 | $121.22 | +11.37% | 16 | Oct 31, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $678 → $740 | $718.36 | +3.01% | 21 | Oct 29, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $226.08 | +10.58% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $455.48 | +6.48% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $52.15 | +5.47% | 16 | Apr 23, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $26.03 | -7.80% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $46.48 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $85 | $99.72 | -14.76% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $155.51 | +6.10% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $35.00 | -42.86% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $181.30 | -0.72% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $8.18 | +633.50% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.72 | +315.92% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.31 | +587.02% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $65.67 | +44.66% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $7.25 | +175.86% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $69.56 | +4.95% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.22 | +883.61% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $3.33 | -54.95% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.22 | +938.78% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $165.72 | +129.30% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $102.52 | -20.02% | 5 | Jan 16, 2019 |
Amgen
Nov 6, 2025
Maintains: Neutral
Price Target: $305 → $315
Current: $329.89
Upside: -4.51%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $109.60
Upside: +2.19%
Eli Lilly and Company
Oct 31, 2025
Maintains: Overweight
Price Target: $925 → $985
Current: $1,010.31
Upside: -2.51%
Gilead Sciences
Oct 31, 2025
Reiterates: Overweight
Price Target: $135
Current: $121.22
Upside: +11.37%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Overweight
Price Target: $678 → $740
Current: $718.36
Upside: +3.01%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $226.08
Upside: +10.58%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $455.48
Upside: +6.48%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $52.15
Upside: +5.47%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $26.03
Upside: -7.80%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $46.48
Upside: -
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $99.72
Upside: -14.76%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $155.51
Upside: +6.10%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $35.00
Upside: -42.86%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $181.30
Upside: -0.72%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $8.18
Upside: +633.50%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.72
Upside: +315.92%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.31
Upside: +587.02%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $65.67
Upside: +44.66%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $7.25
Upside: +175.86%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $69.56
Upside: +4.95%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.22
Upside: +883.61%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $3.33
Upside: -54.95%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.22
Upside: +938.78%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $165.72
Upside: +129.30%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $102.52
Upside: -20.02%